Presented here are few of the products which Vertex Product Development has designed, engineered and developed from conception to production for the Consumer, Commercial, Industrial and Medical industries.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Presented here is an extensive product design and engineering effort, from the ground up of a Semiconductor Wet Processing System. This new system is capable of fully automated, cassette-to-cassette, true single-sided wet processing of 1-12\
Vertex was approached by the client to do a complete re-design of an existing similar product manufactured by the same client, and to have a new product which is more up to date with regards to design style and lower in cost to manufacture.
Typical industrial design & engineering program of an advance electrical meter/monitoring system.
This short clip demonstrate the way Vertex Product Development approach typical design effort/challenge by following step by step design and engineering program.
Vehicles are doing a better job of protecting people in crashes, but a new crop of advanced technology aims to prevent many crashes from happening altogether. A new study by the Highway Loss Data Institute (HLDI) finds that one kind of advanced forward collision avoidance system is working to prevent about a quarter of the common low-speed crashes that happen in everyday commuter traffic.
The study of insurance claims found that Volvo XC60 midsize SUVs outfitted with a standard collision avoidance feature called City Safety are far less likely to be involved in low-speed crashes than comparable vehicles without the system. City Safety is designed to help a driver avoid rear-ending another vehicle in slow-moving, heavy traffic. Claims under property damage liability coverage — the insurance that pays for damage to vehicles that an at-fault driver hits — were filed 27 percent less often for the XC60 than other midsize luxury SUVs.
For more information: www.iihs.org
Presented here are few of the products which Vertex Product Development has designed, engineered and developed from conception to production for the Consumer, Commercial, Industrial and Medical industries.
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Today's SUVs and pickups pose far less risk to people in cars and minivans than previous generations, a new study from the Insurance Institute for Highway Safety shows. Until recently, SUVs and pickups were more likely than cars or minivans of the same weight to be involved in crashes that killed occupants of other cars or minivans. That's no longer the case for SUVs, and for pickups the higher risk is much less pronounced than it had been.
Equal parts travelogue, character study, and global documentary, The Meeting of the Waters is for any Christian leader or layperson eager to make a difference in a changing world. Identifies seven trends having a major impact on the Church around the world-and on every Christian at home in every country.The Meeting of the Waters by Fritz Kling Find out more about this author and book here- http://tinyurl.com/ybcdv8d Christian Ministry
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
